secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001493152-24-020059
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Q1 revenue $2.4M record; raises CyPath Lung forecast 35%
--------------------------------------------------------------------

- Q1 2024 revenue $2.4M vs $921 prior-year; net loss $2.1M ($0.21 per share) vs $1.5M ($0.18).
- CyPath Lung orders annualized growth 547% in first 4 months vs full-year 2023; April up 21% MoM.
- Raised 2024 CyPath Lung sales forecast 35%; PPLS subsidiary revenue forecast $9.2-9.6M (up 23%).
- Medicare reimbursement for CyPath Lung effective Jan 1, 2024; adoption expanding beyond Texas.
- Closed $2.5M registered direct offering; cash $2.5M at March 31, 2024 vs $2.8M Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315224020059/0001493152-24-020059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315224020059/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer